Skip to main content
Premium Trial:

Request an Annual Quote

StemCells to Raise $5.7M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – StemCells Inc. today announced that it will raise $5.7 million through a private placement of its common stock with Seaside 88, a private investment limited partnership.

The Palo Alto, Calif.-based firm said that it will sell 7 million shares to Seaside 88 at a price of $.865 per share, representing a 12.6 percent discount to its closing price on June 29. The company expects to close the deal today.

As part of the agreement, Seaside 88 agreed to purchase an additional 5 million shares of common stock 12 weeks after the initial closing. However, StemCells has the right to not sell the additional shares. If the second placement is made, a purchase price will be calculated using the then-current trading price.

StemCells did not disclose its intended uses for the proceeds from the offering. The firm is developing stem cell-based assay platforms for use in drug discovery, research, and development. It also is developing stem cell therapeutics.

Shares of StemCells closed at $.99 in trade yesterday on the Nasdaq.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more